AstraZeneca drug Lynparza shows promise in prostate cancer trial

April 21, 2015 1:30 PM

8 0

LONDON, April 21 (Reuters) - AstraZeneca's recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday.

The news is the latest boost to the British company's cancer drug pipeline, which formed a central plank of its defence against a $118 billion takeover attempt by Pfizer last year.

Also read: Canada determined to diversify despite Keystone XL approval

Read more

To category page